前立腺癌に対するPeplomycinの臨床効果

Abstract

Peplomycin, a derivative of bleomycin, was used in the treatment of 8 patients with stage D, 2 patients with stage C and one patient with stage B prostatic carcinoma. Newly-diagnosed 4 patients received peplomycin from the outset and other 7 patients had previously received anti-androgenic therapy for 4 months to 10 years. Based on the results of a response study using acid-phosphatase level, prostatic biopsy, urethrocystography and rectal palpation, there was no objective response in all of 4 patients given a total dose of 100 mg of peplomycin. Objective responses were elicited in 5 of 6 patients given a total dose of 165 to 200 mg of peplomycin. However, the response was gentle and not so beneficial because of anorexia, which was one of the severe adverse reactions caused by peplomycin and more or less correlated to the cause of death in 2 of the 6 patients averaging 78 years of age. To relieve the adverse reaction and enrich the beneficial effect, peplomycin was suggested to use in combination with other anticancer treatments including irradiation, hyperthermia and/or anticancer drugs.